Synapse News
Bay Area Health Trust Invests in Hamilton’s “Startup to Watch” – VoxNeuro
Bay Area Health Trust (bayareahealthtrust.com), is a Hamilton based company that operates businesses in the life sciences and seeks strategic opportunities in new technologies in the health and life science fields. VoxNeuro (voxneuro.com) has been dubbed as one of Hamilton’s “startups to watch” from leaders across the industry. For Bay…
Hamilton Health Sciences develops smartphone app to help concussion patients
A Hamilton Health Sciences team has developed an innovative smartphone application that will soon help patients manage the effects of concussions on their daily lives. The MyHeadHealth mobile app will provide concussion patients with a personalized treatment plan, instructional videos, educational tools and a way for them to input information…
Bay Area Health Trust working with McMaster University to Increase Covid-19 Testing Capacity
Bay Area Health Trust (www.bayareahealthtrust.com), a Hamilton, Ontario based company today announced an exclusive licensing agreement for the ‘McMaster Molecular Medium (“MMM”) with McMaster University. Developed by researchers from St. Joseph’s Healthcare Hamilton‘s Disease Diagnostics and Development Group, MMM will enable labs…
Global Pandemic Nexus is Coming to MIP
n the hopes of averting future pandemics, Hamilton’s McMaster University is connecting a number of its top infectious disease clinicians and researchers worldwide to prevent global health threats like antimicrobial resistance. The goal of the Global Nexus for Pandemics and Biological Threats is to ensure Canada and the world are better able…
Bayer and Northpond Ventures Lead USD $55 Million Series A Financing Round for Triumvira Immunologics
Triumvira Immunologics Inc. (“Triumvira”), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD $55 million Series A financing round. The financing was co-led by Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures.…
Fusion Pharmaceuticals increases IPO offering to US$230-million amid strong investor demand
Hamilton’s Fusion Pharmaceuticals Inc. has increased its planned initial public offering on the Nasdaq by half and now hopes to raise up to US$230-million, the biotechnology developer said late Wednesday. The cancer drug developer filed Monday to go public, laying out plans to sell 8.35 million shares at US$14 to US$16 apiece, plus an…
Philadelphia gene therapy developer, backed by $250M, makes first acquisition, Hamilton’s Empirica Therapeutics
Century Therapeutics today announced its acquisition of Empirica Therapeutics to leverage its iPSC-derived allogeneic cell therapies against glioblastoma (GBM). “We are pleased to welcome the Empirica team to the Century family. Their deep expertise and unique capabilities will allow us to accelerate efforts to develop iPSC derived immune…
McMaster University testing new tech at Westdale Smart Home to help seniors live on their own
It doesn’t look that different from the other houses on Whitton Road in Westdale. Two-and-a-half storeys. A bay window. Some mock Tudor stylings. You might think a young family or a bunch of students live there. The smart home is part of a larger research effort by the McMaster Institute for Research on Aging (MIRA), […]
Triumvira Immunologics Announces Fast Track Designation for Its First TAC T-Cell Therapeutic Product Candidate: TAC01-CD19
Triumvira Immunologics, Inc. (Triumvira), a Hamilton-based private, clinical-stage biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for its novel T-cell therapy product TAC01-CD19 in patients…